Lannett Co Inc (NYSE:LCI) is reporting first quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, LCI is expected to report 1Q21 income of $ 0.10 per share from revenue of $ 128.96 million.
For the full year, analysts anticipate top line of $ 537.17 million, while looking forward to income of $ 0.64 per share bottom line.
The Company Outlook
Full Year 2021 topline are forecasted in a range of$ 520.00 million ~ $ 545.00 million
Click Here For More Historical Outlooks Of Lannett Co Inc
Previous Quarter Performance
Lannett Co Inc revealed income for the fourth quarter of $ 0.31 per share, from the revenue of $ 137.92 million. The quarterly earnings 16.22 percent while revenues up 3.05 percent compared with the same quarter last year.
Street analysts expected Lannett Co Inc to report income of $ 0.29 per share on revenue of $ 134.26 million for the fourth quarter. The bottom line results beat street analysts by $ 0.02 or 6.90 percent, at the same time, top line results outshined analysts by $ 3.66 million or 2.73 percent.
Stock Performance
Shares of Lannett Co Inc traded up $ 0.30 or 4.52 percent on Tuesday, reaching $ 6.94 with volume of 292.10 thousand shares. Lannett Co Inc has traded high as $ 6.97 and has cracked $ 6.74 on the downward trend
According to the previous trading day, closing price of $ 6.94, representing a 35.79 % increase from the 52 week low of $ 4.89 and a 47.8 % decrease over the 52 week high of $ 12.72.
The company has a market capital of $ 279.13 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Lannett Co Inc will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.lannett.com
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages.
